Skip to main content

Gout and crystal arthropathies

Clinical trials

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

01-06-2018 | Gout | Article

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricemia: A phase 2a, open-label study

Shiramoto M et al. Rheumatology (Oxford) 2018: key100. doi: 10.1093/rheumatology/key100

30-05-2018 | Gout | Article

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled study

Gunawardhana L et al. Arthritis Res Ther 2018; 20: 99. doi: 10.1186/s13075-018-1593-0

29-03-2018 | Gout | Article

Cardiovascular safety of febuxostat or allopurinol in patients with gout

White WB et al. N Engl J Med 2018; 378: 1200–1210. doi: 10.1056/NEJMoa1710895

26-02-2018 | Gout | Article

Effect of fenofibrate on uric acid and gout in type 2 diabetes: A post-hoc analysis of the randomized, controlled FIELD study

Waldman B et al. Lancet Diabetes Endocrinol 2018; 6: P310–318. doi: 10.1016/S2213-8587(18)30029-9

21-02-2018 | Gout | Editorial | Article

Gout therapies and cardiovascular risk

Editorial Board member Fernando Pérez-Ruiz highlights recent clinical trials evaluating the effect of febuxostat on risk of cardiovascular comorbidities, and discusses alternative treatments for gout patients with cardiovascular disease.

18-02-2016 | Gout | Article

Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout

Baer et al determine that a dual-energy computed tomography (DECT) scanning protocol that includes all lower extremity joints has moderate sensitivity in non-tophaceous and high sensitivity in tophaceous gout.

Baer AN et al. BMC Musculoskelet Disord 2016;17:91. doi:10.1186/s12891-016-0943-9

Image Credits